CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
The three studies demonstrated statistically significant reversal of liver fibrosis with leronlimab monotherapy (compared to an isotype IgG4 control arm with p-values across all 3 studies < 0.01). The first two studies, completed in late 2024, evaluated leronlimab in the STAM™ model of metabolic dysfunction associated steatohepatitis (MASH) with fibrosis in mice who received a single dose of Streptozocin at birth and were then fed a high fat diet from weeks four to twelve. The third study, concluded in January 2025, evaluated reversal of liver fibrosis in mice who received carbon tetrachloride, a liver fibrosis-inducing agent, from birth to sacrifice at day 35.
'The management of patients with advanced liver fibrosis due to a variety of etiologies is an area of enormous unmet need in the field of hepatology. The results of these three preclinical studies support both the biologic activity and potential clinical benefit of leronlimab's ability to bind to CCR5 receptors on hepatic stellate cells, leading to a reversal of established liver fibrosis,' said Melissa Palmer, MD FAASLD, the Company's Lead Consultant in Hepatology.
Dr. Jacob Lalezari, CEO of CytoDyn, added, 'We are very encouraged by these initial findings, which add to the growing body of evidence that leronlimab's core mechanism of action, binding to CCR5 receptors on cells, could translate into a variety of meaningful clinical benefits for patients across a number of medical conditions. As the Company continues to prioritize its oncology objectives for 2025, we look forward to establishing the right partnership to further the clinical development pathway for leronlimab in the treatment of fibrosis of the liver and potentially other organs, such as the lungs and heart.'
CytoDyn is currently in discussions with several third parties regarding next steps in an effort to expand on these promising findings. The Company intends to explore a number of potential synergies and partnership opportunities in the coming months as it furthers its clinical development pipeline, including opportunities that might explore the potential widespread applications for leronlimab as a treatment path for fibrosis in other organs.
About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions.
About SMC Laboratories
SMC Laboratories, Inc. is a CRO, with a focus on conducting the non-clinical research necessary for the drug development process. As a global consulting company that designs studies according to customer requests, it supports cutting-edge non-clinical pharmacological studies. The company owns a variety of mouse models for inflammation and fibrosis in various organs, centered on the innovative STAM™ mouse animal model of liver cancer derived from MASLD (metabolic dysfunction-associated steatotic liver disease). This patented mouse model was developed by SMC Laboratories as a worldwide-first model based on MASLD. We offer non-clinical pharmacological studies using the model mouse. Please check the company's website for further details.
Note Regarding Forward-Looking Statements
This news release contains forward-looking statements relating to, among other things, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2024, including the section captioned 'Forward-Looking Statements' and in Item 1A. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Media Contacts
CytoDyn Inc. Riyaz Lalani Gagnier Communications CytoDyn@gagnierfc.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
DIAGNOS Announces Extension of Stock Warrants Exercise Period
BROSSARD, Quebec, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. ('DIAGNOS' or the 'Corporation') (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 1,414,286 stock warrants (each a 'Warrant') issued as part of a non-brokered private placement of units initially announced on February 27, 2024. The Warrants initial exercise period is set to expire on August 27, 2025. Subject to the TSX Venture Exchange (the 'Exchange') consent, the extended expiry date shall be February 27, 2029 (the 'Amendment'). All other provisions of the Warrants, such as the Warrants exercise price of $0,40 per common share of the Corporation, will remain unchanged and fully in effect during the extended exercise period. One insider of the Corporation holds 357,143 Warrants to be amended. The insider is considered a 'related party' of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). The Amendment is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101, based on sections 5.5(a) and 5.7(1)(a), as the fair market value of the related party participation in the Amendment to Warrants does not exceed 25% of the Corporation's current market capitalization. The board of directors of the Corporation has reviewed and approved the Amendment related to the Warrants to ensure that it was in the best interest of the Corporation and its shareholders The Corporation will issue a follow up press release solely in the case where the Exchange rejects the application for the Amendment. All monies quoted in this press release shall be stated in lawful money of Canada. About DIAGNOSDIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale. Additional information is available at and This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224
Yahoo
an hour ago
- Yahoo
Saudi Arabia $1.85 Bn Consumer Wearables Market Trends, Regional Insights, Competition, Forecast & Opportunities, 2020-2024 & 2025-2030
The Saudi Arabia consumer wearables market is experiencing growth due to a rise in health consciousness and the popularity of online shopping. The demand for fitness trackers and smartwatches is increasing as they offer health monitoring features. Affordability remains a challenge, but integration with health and wellness presents key opportunities. Saudi Arabian Consumer Wearables Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Consumer Wearables Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Saudi Arabia Consumer Wearables Market was valued at USD 0.67 Billion in 2024 and is expected to reach USD 1.85 Billion by 2030, rising at a CAGR of 18.45%. The market's growth is driven by the introduction of devices with advanced features catering to diverse health and wellness needs, the rise of online shopping channels, and an increasing focus on health and fitness. As more individuals prioritize active lifestyles, the demand for wearables is growing. Fitness trackers, smart bands, and smartwatches that monitor activity levels, heart rate, sleep patterns, and other health metrics are gaining popularity. In 2023, Huawei launched the Huawei Band 8 in Saudi Arabia, featuring a 1.47-inch AMOLED display, sleep tracking, heart rate monitoring, SpO2 tracking, and over 100 workout modes. It is compatible with both Android and iOS devices, supports fast charging, and offers extended battery life. Key Market Drivers Rising Health Consciousness and Fitness Trends One major driver is the rising health consciousness among the population. Recently, there has been a focus on maintaining a healthy lifestyle, particularly after the COVID-19 pandemic, highlighting the importance of wellness and preventive healthcare. Consumers are more aware of how physical activity, nutrition, and mental well-being impact health, and wearable technology offers a convenient way to monitor and improve their lifestyle. Fitness trackers, smartwatches, and health-focused wearables are gaining traction as tools for tracking steps, heart rate, sleep patterns, and physical activity. Saudi consumers, particularly the younger and tech-savvy population, are embracing wearable devices to monitor fitness and health. With more individuals adopting regular exercise routines and health-related goals, the demand for devices that help track progress and provide actionable insights is growing. According to the 2023 'Internet Saudi Arabia' report by the Communications, Space, and Technology Commission, both men and women in the country exhibit high internet usage rates, at 99.3% and 98.5% respectively. Mobile phones are the most popular internet access method, accounting for 98.9%, followed by computers at 55% and tablets at 39%. Key Market Challenges High Cost and Affordability Concerns One significant challenge is the relatively high cost of many wearable devices, particularly premium models like high-end smartwatches and fitness trackers. While the market is expanding due to rising disposable incomes and interest in health and wellness, the price of wearable devices can still be a barrier for a significant portion of the population. Premium wearables from brands like Apple, Garmin, or Samsung often come with advanced features, superior design, and high-quality materials, making them prohibitively expensive for many potential buyers, especially individuals in lower income brackets or those unwilling to invest a significant portion of their income in a tech product. Although budget-friendly options are available, top-tier devices, which offer advanced health monitoring and seamless integration with other technologies, are typically out of reach for some consumers. Additionally, Saudi Arabia's young, tech-savvy population may be reluctant to spend substantial amounts on wearables if perceived as non-essential or luxury items. Key Market Trends Integration with Health and Wellness A major trend is the increasing focus on health and wellness integration. With rising health consciousness, more consumers seek wearables that offer advanced health monitoring features beyond simple fitness tracking. These include heart rate monitoring, ECG (electrocardiogram) capabilities, blood oxygen level tracking, and stress level management tools. The emphasis on health has become more pronounced due to a growing awareness of chronic diseases and preventive healthcare. As Saudi Arabia's younger, tech-savvy population becomes more health-conscious, the demand for wearables that help track overall health and wellness is surging. The Saudi government's initiatives to improve healthcare and encourage active living under Vision 2030 have also contributed to this trend. Many wearables now serve as essential tools for managing personal health, offering real-time insights into a person's physical state. As more users adopt wearables for health monitoring, the market is seeing specialized devices developed to target specific health conditions such as diabetes or hypertension. Report Scope: Key Market Players: United Matbouli Group LG Electronics Saudi Arabia Ltd Universal Electronic Appliances LLC Modern Electronics Co. Ltd Alesayi Electronics Co. Ltd Pioneer Corp. Apple Inc. Digital & Electronic Solutions Development Co. Ltd Huawei Device Co., Ltd. Garmin Ltd. Saudi Arabia Consumer Wearables Market, By Product Type: Smartwatches Fitness Trackers Smart Glasses Smart Clothing Hearables Others Saudi Arabia Consumer Wearables Market, By Connectivity: Bluetooth Wi-Fi Others Saudi Arabia Consumer Wearables Market, By Sales Channel: Online Offline Saudi Arabia Consumer Wearables Market, By Region: Western Northern & Central Eastern Southern Key Attributes: Report Attribute Details No. of Pages 82 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $0.67 Billion Forecasted Market Value (USD) by 2030 $1.85 Billion Compound Annual Growth Rate 18.4% Regions Covered Saudi Arabia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Consumer Wearables Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Business Wire
an hour ago
- Business Wire
Paired Power Secures Patent for PairTree™ Solar-Integrated EV Charger System
CAMPBELL, Calif.--(BUSINESS WIRE)-- Paired Power, a leading manufacturer of solar-powered electric vehicle (EV) charging systems, announced the award of U.S. Patent No. 12,375,024 for its innovative PairTree™ solar canopy solution. The patent, titled 'Solar canopy systems and methods,' formally recognizes Paired Power's proprietary approach to solar canopy installation, significantly expanding the deployment speed and accessibility of electric vehicle charging in situations with limited or no grid power. This marks the company's fourth patent since 2016, reinforcing its position as the innovator in solar powered EV charging. The newly patented technology covers a unique method for raising solar panels above a foundation using an integrated lift mechanism. Unlike conventional canopy installations that require elevated work, scaffolding, or external lifts, the PairTree™ system allows panels to be safely assembled at ground level before being elevated into place. This streamlined approach reduces installation time, labor costs, and safety risks, making deployment of EV charging infrastructure faster with fewer approval bottlenecks in a wider range of environments. "Securing this patent for PairTree is a monumental achievement for Paired Power," said Tom McCalmont, CEO of Paired Power. 'It embodies our commitment to making sustainable energy solutions more accessible, efficient, and deployable for everyone, everywhere. The ability to rapidly install solar canopies with minimal effort will accelerate the adoption of electric vehicles by providing charging options in previously underserved locations." PairTree reduces installation time from weeks to hours, enabling rapid deployment with immediate functionality and minimal site disruptions. Unlike traditional EV chargers that require trenching and major construction, PairTree preserves existing parking spaces and reduces or eliminates reliance on the grid during installation. Paired Power's signature combination of solar power and energy storage allows PairTree to create its own self-powered microgrid, further enhancing the solution's utility for remote, off-grid or utility-constrained locations. By generating and storing its own energy, the system also empowers operators to avoid costly demand charges often levied by utilities during peak energy use. Its modular, flexible design enables fast, cost-effective EV charger deployment where and when it's needed most. To learn more about the PairTree™ system, visit To delve further into the company's full suite of microgrid EV charging solutions, join Paired Power on Thursday, September 18, for a live webinar at 2:00pm EDT/11:00am PDT. About Paired Power: Trusted by cities, governments, and leading corporations, Paired Power manufactures solar-powered microgrid electric vehicle charger facilities (EVCF) that enable rapid deployment of new EV infrastructure without requiring expansions of existing grid capacity. Paired Power's flagship products are PairTree™, a microgrid solar powered EV charger that pairs a 4.6kW solar array with a 42.4 kWh Battery Energy Storage System (BESS) to provide Level 2 EV charging day or night, and PairFleet™, a larger microgrid designed to serve greater numbers of vehicle charging needs and can be customized based on a client's energy requirements. For more information about Paired Power, visit
